Abstract: Thyroid Eye Disease (TED, Graves ophthalmopathy, thyroid ophthalmopathy) is the most common cause of orbital inflammation and proptosis in adults. There is no agreement on its management although corticosteroids and external beam orbital radiation (XRT) have traditionally been believed to provide benefit in active inflammation. Our review of the published literature in English disclosed an overall corticosteroid-mediated treatment response of 66.9% in a total of 834 treated patients who had moderate or severe TED. Intravenous corticosteroids used in repeated weekly pulses were more effective (overall favorable response = 74.6%, n = 177) and had fewer side effects than daily oral corticosteroids (overall favorable response = 55.5%, n = 265). A combination of corticosteroid and radiation therapy seemed to be more effective than corticosteroids alone. Our conclusions are tempered by a notable lack of standardization within and between study designs, treatment protocols, and outcome measures. Accordingly,
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Not clearly stated Prospective case series. 1 gm/day IV steroids 3 3, repeat 3-5 times over 5 weeks (total 9-12 gm) followed by 30 The most commonly employed immunomodulators include corticosteroids with or without adjunctive external beam orbital radiation (XRT) in moderate to severe cases of TED. However, disease management varies widely (13) . The goals of medical therapy are to shorten the duration and minimize the severity of the active phase, thereby reducing the chronic phase disfigurement and disability produced by irreversible fibrosis.
Corticosteroids are typically administered orally or intravenously (IV). Local injections of corticosteroids into the orbit have failed to provide an effect in improving orbitopathy (14, 15) . Some studies have shown that local injections can improve motility and extraocular muscle (EOM) size and can be a suitable alternative to patients with contraindications to systemic corticosteroids (16, 17) .
XRT was first used empirically to treat TED. While the mechanism for its action is not fully understood, radiation (XRT, typical total dose = 20 Gy) is biologically active against infiltrating lymphocytes, tissue-bound monocytes, and fibroblasts so as to alter the local cellular matrix and interrupt the inflammatory process in a more permanent fashion than can be achieved with corticosteroids (14, 18) . One recent prospective, double-masked, sham-controlled clinical trial produced more debate than consensus regarding the efficacy of XRT therapy for TED (19, 20) .
There is no agreement on the management of TED (18, 21, 22) . As an alternative to corticosteroids and XRT, other immunomodulatory agents such as azathioprine, cyclosporine, intravenous immunoglobulin (IVIg), and plasmapheresis have been used, but they play a more limited role (23) (24) (25) (26) (27) (28) . Efficacy studies have not been well modeled, and are mainly small, retrospective, or uncontrolled (18, 21, 22, 29, 30) . Interpretation of the data from the existing studies is limited by the lack of good natural history data and the highly variable nature of the disease. We have evaluated the relevant publications in the English language to compare the outcomes of TED patients treated with corticosteroids and/or XRT.
METHODS
We performed a review of published studies identified in a PubMed on-line review from January 1966 to July 2006 using the following key words: Graves ophthalmopathy, thyroid eye disease, Graves disease, and thyroid orbitopathy. Inclusion criteria required at least eight enrolled subjects within a retrospective or prospective study published in the English language. Our review compared the outcomes of using corticosteroids with or without XRT. We included only those studies that compared the outcomes through definable measurements, orbital imaging studies (CT or MRI), self-assessment surveys, or clinical examinations.
RESULTS

Study Profiles
We identified nineteen studies for our review. Seven had enrolled patients in randomized prospective studies (12, 14, 28, (30) (31) (32) (33) ; the remainder were either prospective or retrospective case series.
General Patient Treatment Profile
A total of 834 patients from nineteen studies were reviewed. Study patient populations were dissimilar, and inclusion and exclusion criteria varied. In particular, some studies excluded patients who had had prior treatment for TED (12, 14, (31) (32) (33) (34) . Others included patients that had already been treated with XRT, immunomodulatory agents, or decompressive surgery (21, 28, 30, (35) (36) (37) (38) (39) (40) . Still others failed to detail prior treatment (41) (42) (43) (44) . The study of Marcocci et al (30) was the only one that detailed the thyroid metabolic status of the patients such that 81 (99.8%) of 82 patients presented with hyperthyroidism and TED; one patient had euthyroid TED.
Of the 834 patients, 597 (71.6%) from 13 studies were treated with oral corticosteroids with or without XRT. Of the 597 patients, 265 had received only oral prednisone (average of 76 1/2 26 mg/day). The length of oral corticosteroid treatment (including taper) averaged 17.5 1/2 5.4 weeks. In 10 studies, 237 patients (28.4%) were treated predominantly with IV corticosteroids (methylprednisolone) with or without XRT. Seven of these studies mainly used 1000 mg/pulse and the remaining three studies used a 500 mg/pulse. The average number of pulses received was 5.8 1/2 3.8 over an average length of 13 1/21.5 weeks of treatment. Most of the patients who had received IV corticosteroids (n = 177) without XRT had also received oral corticosteroids between pulses of IV corticosteroids and were given a tapered course of oral corticosteroids that averaged 37.9 1/2 4.9 mg/day over 14 1/2 17 weeks. The follow-up interval for all studies averaged 59 weeks (range 12 weeks to 3 years) ( Table 1) .
Clinical Measurement of Disease Severity and Treatment Response
TED severity and activity were assessed using different scoring systems, including the NOSPECS classifi- The NOSPECS classification system was most commonly used (12 of 19 studies). It documents the presence of specific symptoms and signs of which only some are characteristic of active disease. The CAS was used in 6 of 19 studies. It takes into account seven clinical measurements and assigns a point to each symptom or sign (retrobulbar pain, pain on eye movements, eyelid erythema, conjunctival injection, chemosis, swelling of the caruncle, eyelid edema or fullness). Many studies included selfassessment patient surveys (Table 1) .
Neuroimaging
Ten studies employed neuroimaging to measure the outcome of TED treatment (12,28,33,34,36-38,40,42,44) . CT, MRI, and B-ultrasound were used to evaluate EOM size. There was no standardized grading protocol ( Table 1) . All studies showed an overall improvement in EOM thickness or proptosis after oral or IV corticosteroid treatment with and without the use of external beam radiation (x-irradiation, XRT). The degree of improvement correlated well with the overall favorable response reported by clinical measures. Matejka et al (37) measured the amount of proptosis on CT and found an overall improvement in all eight patients who had received predominantly IV corticosteroids. The study of Hiromatsu et al (44) was unique in using MRI to judge response in patients treated predominantly with IV corticosteroids. The activity of TED was measured by MRI signal intensity of the EOMs as well as their thickness. Baschieri et al (34) found reduction in EOM thickness on CT after oral prednisone 80 mg/day for a total two weeks with a five month taper. One of the studies employed B-ultrasound to note significant greater reduction in EOM thickness in patients who had received IV corticosteroids than in those who had received oral corticosteroids (33) .
Intravenous vs. Oral Corticosteroids
Because of dissimilar assessment measures within and among studies, treatment outcomes are reported in relation to each study's outcome measures. We judged the results as favorable if the author reported the results as either good or excellent.
Corticosteroids were the primary medical therapy used to treat active TED. There was an overall 66.9% favorable response to corticosteroid treatment among all 834 patients, which included those that may also have been treated with XRT. A total of 442 patients were treated with oral or predominantly IV corticosteroids alone. A total of 151 (55.5%) of 265 patients treated with oral corticosteroids alone had a favorable response, and 132 (74.6%) of 177 patients treated with IV corticosteroids alone had a favorable response.
Patients who had received predominantly IV corticosteroids seemed to have greater improvement in diplopia, ocular motility, and proptosis than those who had received only oral corticosteroids. But patients who received only oral corticosteroids showed a greater improvement in EOM thickness than patients who received predominantly IV corticosteroids ( Table 2) .
Two prospective randomized studies compared IV to oral corticosteroid treatment (30, 32, 33) . Neither of these studies used a tapered regimen of oral corticosteroids followed a regimen of IV corticosteroids. Kahaly et al (33) showed an improvement in the CAS in 27 (77%) of 35 patients treated with IV corticosteroids as compared to 18 (51%) of 35 patients treated with oral corticosteroids. Based on a self-assessment survey, 80% of patients receiving IV corticosteroids as compared to 54% receiving oral corticosteroids were satisfied with the treatment results and had an improved quality of life. Macchia et al (32) reported similar results, such that 21 (84%) of 25 patients treated with IV corticosteroids had a favorable response as compared to 15 (57%) of 26 treated with oral corticosteroids. However, proptosis improved equally among both groups.
Combined Corticosteroid and XRT Treatment
The cumulative radiation dose and the radiation field were similar in nearly all studies (Table 1) . A total of 20 Gy was delivered to each orbit over a period of two weeks. There was an overall 70.2% favorable response in the 392 patients who underwent both XRT and IV or oral corticosteroid treatment. Compare this to an overall 64.0% favorable response in the 442 patients who received IV or oral corticosteroids without XRT. More specifically, 223 (67.2%) of 332 patients who received oral corticosteroids and XRT (14,21,30,35,39 ) responded favorably as compared to 52 (86.7%) of 60 patients who received predominantly IV corticosteroids and XRT (30, 36, 40) ( Table 2) .
One prospective randomized study compared the outcome following IV corticosteroids and XRT to the outcome following oral corticosteroids and XRT. Marcocci et al (30) found a significantly greater short-term improvement of periocular edema, erythema, orbital ache, and ocular motility in patients who had received IV corticosteroids and XRT (88%) when compared to oral corticosteroids and XRT (63%). Proptosis improved in 19 (47.5%) of 40 patients receiving IV corticosteroids and XRT and in 16 (40%) of 40 patients receiving oral corticosteroids and XRT. Optic neuropathy improved in 13 (92%) of 14 patients after treatment with IV corticosteroids and XRT, but only in 3 (33%) of 9 patients who received oral corticosteroids and XRT. This difference, however, was not statistically significant (30) .
Intravenous vs. Oral Corticosteroid Treatment With or Without Adjunctive XRT
Overall, treatment with pulsed IV corticosteroids was more effective and better tolerated than chronic treatment with oral corticosteroids alone. Oral corticosteroids produced a favorable response in 62.6% of patients with or without the use of XRT (n = 597). This compares to a favorable response in 77.6% of patients treated with IV corticosteroids with or without XRT (n = 237). In the studies reporting results, the patients who received predominantly IV corticosteroids showed greater improvement in diplopia, ocular motility, and proptosis in comparison to those who received oral corticosteroids with or without adjunctive XRT. In contrast, the patients who received oral corticosteroids showed a greater improvement in EOM thickness in comparison to the patients who received predominantly IV corticosteroids with or without adjunctive XRT (Table 2) .
Corticosteroid Side Effects
There was a higher rate of side effects to corticosteroids administered via the oral route than to corticosteroids administered via the IV route. Chronic oral corticosteroid treatment was associated with Cushingoid facies, weight gain, osteoporosis, gastric irritation, labile hypertension, elevated intraocular pressure, elevation in blood sugar, and mood alteration. Marcocci et al (30) documented that 35 (85.4%) of 41 patients treated with an approximately six-month oral corticosteroid taper (starting at 100 mg prednisolone by mouth daily for a cumulative dose of 6 grams) demonstrated side effects including weight gain, urinary tract infections, transient hyperglycemia, and decreased bone mineral density. Three patients who had received oral steroids in the randomized study of Macchia et al (32) had to withdraw from their treatment due to ''severe signs or symptoms of hypercortisolism.'' Prummel et al (12) found that 25 of 28 patients who received a 20-week oral corticosteroid taper (starting at 60 mg prednisolone by mouth daily for four weeks followed by a taper) experienced only minor side effects. One patient developed depression and a second patient manifested a recurrent herpetic zoster eruption. Baschieri et al (34) reported two cases of hemorrhagic gastritis in patients receiving 80 mg prednisone by mouth daily with a 5-month taper. One patient developed bipolar disorder. More frequent side effects included Cushingoid facies (5 out of 30 patients) and abnormal glucose tolerance (5 out of 30 patients).
Intravenous corticosteroid treatment was associated with a lower rate of adverse side effects. Kahaly et al (33) reported adverse events in only 6 (17%) of 35 patients, including weight gain, insomnia, palpitations, and gastrointestinal discomfort. However, Marcocci et al (30) reported adverse effects in 23 (56.1%) of 41 patients, including urinary tract infections and impaired glucose tolerance. Nine patients inexplicably had a mean percentage increase in bone mineral density after IV corticosteroid treatment. One patient had transient elevation of serum aminotransferase levels (34) .
Radiation Side Effects
Radiation was well tolerated and produced few shortterm side effects. Koshiyama et al (36) , Marcocci et al (30) , Staar et al (39) , and Prummel et al (12) reported no side effects from radiation. In the study of Bartalena et al (21) , with a follow-up over 26 months, there were no new cataracts. However, Prummel et al (12) found that 15 (54%) of 28 patients surveyed had side effects, usually minor, including transient hair loss at temples, tiredness, myalgias, headaches, insomnia, and nausea.
Reactivation of TED After Treatment
Seven of the reviewed studies addressed the incidence and timing of disease recurrence after successful initial treatment (21, 32, 35, 36, 39, 42, 43) . The study of Koshimaya et al (36) found no recurrence of TED among all eight patients who had received predominantly IV corticosteroids and combined XRT after a three-year follow-up. The study of Macchia et al (32) found no recurrence of TED among 51 patients who had received either oral (n = 26) or IV corticosteroids (n = 25). However, four other studies reported substantial recurrence in treated patients. Chang et al (42) reported that 4 of 10 patients worsened when the oral corticosteroids were discontinued or quickly tapered to 20 mg/day over a course of five months. Noth et al (35) documented that 12 (63.2%) of 19 patients followed for three years required further immunosuppressive therapy and XRT due to disease recurrence or progression. Staar et al (39) also reported that because of disease progression or recurrence, 72 (32%) of 225 patients eventually proceeded to orbital decompressive surgery after a year's treatment with a combination of oral corticosteroids and XRT.
Summary of Outcomes
A review of the published literature in English has suggested that corticosteroid-mediated treatment produces benefit in 66.9% in TED patients who have moderate to severe disease. IV corticosteroids used in repeated daily or weekly pulses (average of 5.8 pulses/treatment epoch) were more effective than daily oral corticosteroids. Intravenous administration of corticosteroids appeared to be more effective than oral administration alone. A combination of corticosteroids and XRT was more effective than corticosteroids alone. In combination with XRT, IV administration of corticosteroids was more effective than oral administration.
Intravenous corticosteroids were associated with fewer side effects than oral corticosteroids. However, single case reports not included in this series have reported fatal cardiac and fatal hepatic necrosis with the use of IV corticosteroids for TED (45, 46) . XRT appeared to be well tolerated with few if any side effects. However, a report by Gorman et al (20) , not included in this review, discovered newly dilated capillaries or microaneurysms on fluorescein angiograms or fundus photographs in five eyes among 3 of 37 treated patients three years after receiving XRT.
Among the three prospective randomized studies, IV corticosteroids had a clear benefit in treatment outcome over oral corticosteroids (30, 32, 33) . Patients treated with IVor oral corticosteroids showed improvement in proptosis, diplopia, ocular motility, and in self assessment of benefit, but the treatment outcomes were more substantial in those treated with IV corticosteroids (over 77% favorable outcome) than with oral corticosteroids (up to 62% favorable outcome). The only study (12) that compared oral corticosteroid administration to XRT in a prospective, doubleblind randomized trial showed similar treatment outcomes (self assessment, EOM size on CT), but XRT seemed to improve ocular motility more than did oral corticosteroids, while oral corticosteroids seemed to improve soft tissue swelling more effectively.
Cautions
Caution is warranted regarding the interpretation of outcomes in the studies we have reviewed. The studies differed in design, treatment protocol, and outcome measures. The potential clinical impact of corticosteroids and XRT in the treatment of TED was difficult to assess reliably. These studies provide little insight regarding pathophysiology or effect of treatment on quality of life.
It was particularly difficult to interpret the results of TED severity and activity among different scoring systems. NOSPECS was the most commonly used scoring system yet it documents manifestations not always characteristic of active disease. Clinical worsening may not represent increased inflammatory activity but rather progressive fibrosis associated with resolving inflammation. CAS, another scoring system used in several of the studies reviewed, does not provide information regarding overall progression or severity of TED. Self-assessment surveys used to document improvements in quality of life are nonstandardized and difficult to interpret across studies. The identification of active TED remains an imperfect combination of the patient's impression and the clinician's interpretation of the physical signs.
We conclude that there is inadequate case-based evidence to ascertain reliably whether medical therapy with corticosteroids or XRT shortens the active phase of disease or improves long-term disfigurement and disability in patients with moderate to severe TED. To answer this question more rigorously, the North American NeuroOphthalmology Society (NANOS), American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS), and the Orbital Society, working in conjunction with Neuro-Ophthalmology Research and Development Consortium (NORDIC), have established a committee to pursue the design and funding of a large, multi-center, double-masked, placebo controlled study.
